Treatment history influences the outcomes of subsequent therapies in patients with relapsed or refractory multiple myeloma (RRMM) and needs to be considered when deciding which treatment to use next. To assess the relative merits of immunomodulatory (IMiD)-free treatments, a systematic literature review (SLR) was conducted to identify relevant randomized controlled trials in patients with RRMM. A network meta-analysis (NMA) was performed to assess various IMiDfree regimens, including bortezomib and dexamethasone (Vd)-based treatments, and to explore differences in patient outcomes. The SLR identified 52 articles, from which four trials were ultimately included in the base-case NMA. The NMA showed that daratumumab plus Vd (DVd) provided a significant advantage in prolonging progression-free survival. Similar trends were observed for overall survival and overall response. Across all outcomes, DVd had the highest probability of being the best treatment. These findings suggest that DVd may provide superior clinical outcomes for RRMM patients suitable for IMiD-free regimens.
Introduction
Patients with multiple myeloma (MM) typically relapse on, or become refractory to, therapy, thus necessitating a change in treatment [1] . This development of relapsed or refractory MM (RRMM) is commonly associated with progressive disease symptoms and treatment-related complications and, therefore, a substantial clinical and emotional burden. In addition, once a patient becomes nonresponsive to previous treatments, overall survival (OS) and other outcomes deteriorate with an increasing number of prior lines of therapy (LOTs) [2, 3] . This complicates the selection of subsequent treatment, as does the fact that characteristics of previous therapy can have a major influence on outcomes of later interventions (i.e. they act as treatmenteffect modifiers). Consequently, clinicians must consider various factors before assigning patients with RRMM to a specific treatment regimen, including each individual's prior treatment history and regimen-related toxicity [4] . In many cases, such decision-making requires selection of appropriate therapy for patients who have experienced a first relapse while on a regimen based on an immunomodulatory drug (IMiD), particularly lenalidomidea treatment widely used in this frontline setting in both transplant-eligible and transplant-ineligible individuals.
Against this background, clinical practice guidelines from the European Society for Medical Oncology (ESMO) [5] and the Mayo Clinic [6] recommend that patients experiencing a first relapse after IMiD-based induction therapy should be switched to IMiD-free regimens, such as treatments based on the combination of bortezomib and dexamethasone (Vd). Clinicians facing this, and other scenarios in which an IMiD-free regimen is a suitable choice, require a clear evidencebased understanding of how the various treatment options compare in terms of response and survival. Such insight is hampered, though, by the lack of head-to-head randomized controlled trials (RCTs) of the available IMiD-free regimens. Comparisons of these regimens have been made within previous network meta-analyses (NMAs) that included studies of CONTACT Annette Lam alam4@its.jnj.com Janssen Global Services, 700 US 202 Raritan Ave, Raritan, NJ 08869, USA Supplemental data for this article can be accessed here.
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IMiD-containing, as well as IMiD-free, regimens. However, this approach of combining the study results for the two treatment types is likely to be subject to bias due to the assumptions required to link the two evidence networks, given that these differ fundamentally with regard to their patient populations and the clinical questions they have investigated. Furthermore, such a method presumes that all treatment choices for RRMM are equally applicable, regardless of a patient's treatment history and other factors that determine the suitability of any particular option.
Consequently, the compromises that were required to conceive and conduct the previous NMAs mean that these analyses were not designed to address a key research question -What is the relative efficacy of the various IMiD-free combination treatments in those patients with RRMM for whom such a regimen is the preferred choice? In theory, the previous NMAs provided data potentially relevant to this question. However, the certainty of these findings is undermined by the inclusion of the trials of IMiD-containing regimens in the networks, which also would have led to very marked heterogeneity in the evidence used to estimate the comparative effects of IMiDfree regimens.
Accordingly, there is a need for more definitive information on comparative treatment efficacy that would help clinicians decide between IMiD-free regimens where such therapy is appropriate. To address this gap, the current study used an NMA to examine specifically comparisons of IMiD-free combination regimens in patients with RRMM.
Methods

Systematic literature review
Literature search and study selection
Indexed databases were searched for potentially relevant articles published in English between 1 January 1995 and 3 November 2016, using the search strategies shown in the Appendix (Online Material). Key conference proceedings from January 2013 to November 2016 were also checked for relevant abstracts. In addition, the reference lists of SLRs and meta-analyses identified by the search were manually reviewed for additional studies that were not identified directly by the search itself. Documents from the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) were also reviewed for any relevant data that would have otherwise been missed.
Studies were selected for inclusion based on the population, interventions, comparators, outcomes, study design, and time point (PICOS-T) criteria outlined in Table 1 . This selection was done by two independent investigators, who each screened all abstracts and full-text articles. Conflicting opinions between these investigators about the eligibility of individual studies were resolved by a third investigator. Articles meeting all inclusion criteria and no exclusion criteria were included in the SLR, with additional selection criteria being subsequently added to explore studies' suitability for inclusion in the NMA (see Table 1 ).
Data collection and quality assessment
Information on study, patient, and treatment characteristics and efficacy outcomes were extracted from the reports of the included studies by one investigator and then validated by a second investigator. With regard to clinical outcomes, hazard ratios (HRs), including 95% confidence intervals, were extracted for progression-free survival (PFS) and OS, as well as the proportion of patients with overall response (overall response rate [ORR]). Where HRs were not reported, data were imputed from Kaplan-Meier (KM) curves for PFS and OS. Study quality was assessed using the Centre for Reviews and Dissemination guidance document checklist [7] , with each trial being assigned an overall rating of quality, as appropriate.
Development of the network
An assessment was made on the feasibility of conducting an NMA of efficacy outcomes in the identified RCTs. This was informed by eliciting views from key opinion-leaders and clinical experts on the comparability of the patient-selection criteria that had been used in the individual studies. RCTs were considered for the NMA only if they had two or more treatment arms of interest for the network of IMiD-free regimens. The additional inclusion criteria used to determine the final selection of studies for inclusion in the NMA are presented in Table 1 . RCTs that had compared different administration routes, doses, or schedules of a particular regimen were excluded from the NMA.
Analysis
The NMA combined direct and indirect estimates of relative treatment effects into a single analysis using a Bayesian approach. This method involves using statistical modeling to estimate relative effects for all treatments versus all others, as well as generate probabilities (given underlying assumptions) that a given treatment is the best. All analyses were conducted within a Bayesian framework using OpenBUGS 3.2.2 software [8] . The Bayesian NMA involved a 50,000 run-in iteration phase and a subsequent 50,000 iteration phase for parameter estimation. As there was only one study per treatment comparison, only fixedeffects models were fitted, and it was not possible to test for statistical heterogeneity or inconsistency in effects. The NMA produced the following outputs:
Point estimates: HRs for OS and PFS and odds ratios (ORs) for overall response, with credible intervals (CrIs).
A treatment was considered more effective than another when a 95% CrI for an HR or OR did not cross the value 1.0 (equivalent to a Bayesian probability for this pairwise comparison p ! 97.5%). Bayesian pairwise probability that the treatment of interest was more effective than the other comparators assessed in the network. The probability that each treatment ranks in a certain order within each evidence network per outcome analyzed.
Rank probabilities are based on the location, spread, and overlap of the posterior distributions of the relative treatment effects. These rankings can be presented on a rankogram, in which each treatment is represented by a line plot of the specific probability (as plotted on the y-axis) that it ranks first, second, third, etc.
(as plotted on the x-axis). The probability that each treatment has a given rank or higher among all the treatments assessedthe surface under the cumulative ranking (SUCRA).
The SUCRA presents this cumulative probability visually by plotting it (on the y-axis) against treatment rank (on the x-axis) for each treatment included in the network. Rank probabilities presented in rankograms and SUCRA plots complement each other when presenting the probability of a treatment achieving a rank or being the first among the best two options, the best three options, and so on, among all options. However, although SUCRA plots and rankograms provide useful information on treatments' rankings, they do not describe relative effect sizes. In addition, the rankings generally correspond closely to the effect estimates presented by forest plots.
Subgroup analyses
To assess the robustness of results from the base-case analysis, subgroup analyses for PFS were conducted. These explored whether or how clinically meaningful treatment-effect modifiers affected the NMA results. Specifically, these analyses involved stratification by previous LOT (one prior LOT vs. two or more prior LOTs), patients with/without prior bortezomib exposure, and patients with/without prior IMiD exposure.
Results
Study selection
The indexed database search yielded 2161 citations and an additional 85 meeting abstracts. After removing duplicate publications, 1583 unique abstracts were screened, of which 285 full-text publications and conference proceedings were considered relevant for full review. Ultimately, 233 studies were excluded during this full-text screening, consisting of 96 trials that did not meet the SLR inclusion criteria and another 137 that could not be included in the NMA as they did not connect to a network (n ¼ 88), the comparator was not relevant (n ¼ 32), or they compared only doses or modes of administration of a particular regimen (n ¼ 17). The 52 articles left were eligible for inclusion, 7 of which met the selection criteria for inclusion in the NMA (see Figure 1 for the PRISMA diagram of RCT selection).
Summary of network geometry
Seven RCTs were included in the network (Figure 2 ), all of which excluded patients who were refractory to bortezomib. The base-case network was composed of four trials that evaluated carfilzomib plus dexamethasone (Kd) [9] , cyclophosphamide plus Vd (CVd) [10] , daratumumab plus Vd (DVd) [11] , and panobinostat plus Vd (FVd) [12] , with Vd being the reference treatment. The three trials excluded from the base case evaluated elotuzumab plus Vd [13] , thalidomide plus Vd [14] , and thalidomide plus dexamethasone [15] . They were excluded from the base case because, compared to the other four studies, they had clearly different treatment populations (e.g. different treatment history [i.e. autologous stem cell transplantation or melphalan]) or an irrelevant comparator not routinely used in clinical practice (e.g. elotuzumab in combination with Vd).
However, these three trials were included in the sensitivity analyses. Of the four base-case studies, three included patients who had received one to three prior LOTs, while one trial included patients who had received at least one prior LOT with no upper limit. Also, all of the included base-case studies used similar dosing for Vd, with only slight differences in route of administration and treatment duration that were not considered significant enough to affect the validity of the NMA (a conclusion supported by a phase III RCT that reported similar efficacy outcomes for subcutaneous and intravenous administration of bortezomib [16] ). The individual trial data inputted in the NMA are presented in the Appendix (Online Material).
Results of the sensitivity analyses are included in the Appendix (Online Material). A summary of studies is presented in Table 2 . The primary publications of the basecase trials were of low to moderate quality. The quality assessment tables are presented in the Appendix (Online Material).
Synthesis of results
Fixed-effects analyses showed that, in patients with RRMM, DVd prolonged PFS (i.e. demonstrated a statistical advantage, with an HR less than 0.80 and CrIs not crossing 1.0), when compared with other IMiD-free regimens (such as Kd, FVd, CVd, and Vd) ( Figure 3(A) ). FVd and Kd demonstrated a statistical advantage in improving PFS compared with Vd, and CVd demonstrated a trend to improve PFS, but with a CrI that crossed 1.0. There was also a trend for Kd to improve PFS compared with FVd. Results were inconclusive for the comparisons of CVd to Kd and to FVd, respectively. The cumulative rank probability (presented in Figure  3 (A)) shows that DVd had a nearly 100% probability of being the best treatment for prolonging PFS among all regimens included in the NMA. In terms of OS, fixed-effects analyses showed that DVd had a statistical advantage in improving the outcome compared with Vd, and a trend toward improvement compared with Kd, FVd, and CVd (Figure 3(B) ). CVd and FVd did not demonstrate any advantages against other comparators. There was a slight trend for Kd to improve OS when compared with Vd. As shown in the cumulative rank probability graph, DVd had the highest probability of being the best treatment in improving OS, compared to other IMiDfree regimens.
When assessing overall response, patients with RRMM who received DVd were more likely to achieve such an outcome (i.e. demonstrated a statistical advantage with an OR greater than 1.25 and with CrIs not crossing 1.0) compared with those who received Vd or 
Subgroup analyses
The results of the subgroup analyses were generally consistent with those of the base-case analysis for PFS. In patients who had received one prior LOT, there was an additional statistical advantage for DVd in prolonging PFS compared with all other IMiD-free regimens, and for FVd or Kd compared with Vd (Figure 4(A) ). However, there were no added advantages in terms of HRs for PFS in patients who received two or more prior LOTs. In the subgroup of patients who had not received prior bortezomib, there was an additional advantage for DVd compared with FVd and with Vd, while no further advantages were observed for other comparators or for patients who had received prior bortezomib (Figure 4(B) ). For patients with no prior IMiD exposure, there was an increased advantage for DVd compared with FVd and Vd, and for Kd compared with Vd (Figure 4(C) ). Also, patients who had received a prior IMiD continued to experience longer PFS when treated with DVd than with all other comparators.
Discussion
IMiD-free regimens are preferred treatment options and are recommended based on treatment guidelines for RRMM patients who have experienced a first relapse after IMiD-containing frontline treatment. Selection of the most suitable IMiD-free regimen needs to be informed by appropriate evidence on comparative efficacy to best serve the welfare of patients. The lack of head-to-head RCTs of IMiD-free combination regimens as a source of such data has paved the way for NMA methodology to provide important and robust information on the relative effects of these treatments, and the current analysis offers such insight. The analysis found that DVd prolonged PFS and OS, and was more likely to produce an overall response, compared with other IMiD-free regimens. These results provide an important context for the CASTOR trial [11] , which showed that, compared to Vd, DVd resulted in significant improvement in PFS and ORR in Outcome not explored in sensitivity analysis.
ASCT: autologous stem cell transplantation; CR: complete response; HDM: high-dose melphalan; HR: hazard ratio; KM: Kaplan-Meier; LOT: line of therapy; NR: not reported; ORR: overall response rate; OS: overall survival; PFS: progression-free survival; PI: proteasome inhibitor; PR: partial response; sCR: stringent complete response; SCT: stem cell transplantation; VGPR: very good partial response.
patients with RRMM who had received at least one prior therapy. Also of note, very recently released long-term follow-up data for CASTOR has shown that this trend continues beyond the first year. Accordingly, results from this NMA should help to guide the choice of therapy for policy-makers/clinicians when managing patients with RRMM who relapse after first-line treatment with IMiD-based regimens. The results also complement published advice in the ESMO [5] and Mayo Clinic guidelines [6] , both of which recommend switching drug class to an IMiD-free regimen for patients who are refractory to prior IMiD treatment. Specifically, ESMO states that, once licensed, daratumumab triplet combination therapies may be considered standard of care for patients with RRMM. The Mayo Clinic also recommends that patients who are refractory to an IMiD-containing regimen should receive DVd as the next line of therapy.
The findings presented here need to be considered in the light of the previous NMAs, which combined IMiD-containing and IMiD-free regimens in one network for all RRMM patients, and in doing so have provided estimates of the comparative effectiveness of these regimens. Crucially, though, this approach assumes that the patient populations were comparable across all treatment combinations and requires the use of alternate types of evidence or additional assumptions to connect the networks, given the lack of headto-head RCTs. By comparison, separate analyses of IMiD-free regimens, as presented here, provide a more robust approach and hold more strongly to the assumptions of transitivity and consistency necessary for the conduct of a valid and reliable NMA. In particular, a key strength of the current analysis is that the comparability of the patient populations across both IMiD-containing and IMiD-free regimens was not assumed, an important factor given that these populations have major differences regarding treatmenteffect modifying consequences of prior treatment history. By separating the IMiD-free regimens into a single network for patients receiving at least one prior LOT and conducting relevant subgroup analyses, this study provided greater opportunities than the past NMAs for eliminating crucial imbalances in treatmenteffect modifiers related to previous therapies. Another advantage was the exclusion of studies with patient populations that differed substantially from those of the base-case studies (e.g. in terms of treatment exposure or previous LOT). This allowed for the exploration of key potential treatment-effect modifiers in sensitivity analyses, the results of which were then used to validate the results of the base case. It is also important to recognize that results of the current analysis are, in fact, consistent with those of the previous NMAs that combined IMiD-containing and IMiD-free regimens in one network [17] [18] [19] . These analyses also showed that daratumumab combination therapies had the highest probability of being the best treatment option for patients with RRMM. It therefore appears reasonable to speculate that the compatibility of our results with the earlier analyses reflects the certainty of the underlying differences in efficacy between the treatments assessed. In that sense, the previous NMAs could be considered as a valuable form of extended sensitivity analysis for the current findings. Specifically, they provide further reassurance that, even when a broader range of studies is connected using additional assumptions to explore the comparative effectiveness of IMiD-free regimens, the key conclusion of our more methodologically stringent analysis still holds.
Limitations of the current study are that additional analyses that control for differences in patient baseline characteristics via meta-regression techniques were not feasible for this analysis, as each treatment comparison was informed by only a single study. In addition, safety outcomes were not considered in this analysis. Due to the inconsistent reporting and heterogeneous definitions of adverse events, these analyses may not be most appropriate for inclusion in a robust NMA comparison. Rather, the focus was solely on the relative efficacy of licensed treatments as a primary determinant of therapeutic choice for patients with RRMM.
Conclusions
These findings provide policy-makers and clinicians with important evidence regarding the comparative effectiveness of different IMiD-free treatment regimens in patients with RRMM who have received at least one prior LOT. This NMA demonstrates the value of daratumumab as a treatment option in combination with Vd, with respect to treatment response and survival advantages over other relevant IMiD-free treatments. Results from the subgroup analyses based on treatment history were largely consistent with the base case, with additional benefits being observed for patients treated with DVd who received one prior LOT. This review includes the most comprehensive evidence base available; therefore, the results can be considered generalizable to the broader RRMM population for whom an IMiD-free regimen is suitable.
